Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
Publication year
2019Author(s)
Source
Lancet Haematology, 6, 4, (2019), pp. e170-e171ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Haematology
Tumorimmunology
Journal title
Lancet Haematology
Volume
vol. 6
Issue
iss. 4
Page start
p. e170
Page end
p. e171
Subject
Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life SciencesThis item appears in the following Collection(s)
- Academic publications [227425]
- Faculty of Medical Sciences [86157]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.